Pharmaceutical

China approves InnoCare Pharma’s BTK inhibitor for lymp...

China’s NMPA has approved InnoCare Pharma’s orelabrutinib for use as a first-lin...

Granite Bio secures $100m in funding for new antibodies

Granite Bio has secured $100m in funding for its new antibody treatments that ta...

EC grants orphan drug designation to Dyne Therapeutics’...

The EC has granted orphan drug designation to Dyne Therapeutics’ DYNE-251 for tr...

Top 20 biopharmas’ market cap rises 6% in Q1 2025 amid ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncer...

MSD’s Gardasil sales slide further due to China constra...

MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufact...

Challenges in filling for alum drug products: What does...

CDMOs are crucial partners in alum-based vaccine production, managing aseptic fi...

Thermo Fisher counters tariffs with $2bn investment int...

Following in the footsteps of several pharma companies, life sciences giant Ther...

Merck KGaA nears $3.5bn deal for SpringWorks

Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, ...

FDA free to pursue semaglutide compounders after latest...

Despite the decision being a win for Novo Nordisk, the compounded drugs sector i...

FDA approves Akeso’s monoclonal antibody for nasopharyn...

The FDA has granted approval to Akeso's differentiated programmed cell death pro...

Caribou cuts pipeline and workforce to focus on lead CA...

Caribou is scaling back its operations, halting multiple programmes, and cutting...

Veraxa to go public in $1.6bn SPAC deal with Voyager

Veraxa Biotech will gain access to $253m in cash from Voyager to advance its can...

Synthetic hormones and the future of contraception

Contraception for women has seen little change over the past 50 years, with the ...

EditCo Bio secures access to Promega’s technologies in ...

EditCo Bio has entered a licensing agreement to secure access to Promega’s prote...

FDA layoffs and priority review programme’s lapse disru...

The expiration of the FDA’s paediatric priority review voucher programme is crea...

Boehringer to expand oncology presence with $572m Tesse...

The agreement gives Boehringer access to Tessellate’s novel approach targeting A...